Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
May 16, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for June 15, 2005 Subscribe to this News Feed      
 

Eli Lilly Agrees to Pay Approximately $700M in Zyprexa Settlement - Brown & Crouppen Poised to Assist Victims

On Thursday, June 9, 2005, Eli Lilly & Co. announced that it will pay $690 million to settle approximately three-quarters of the liability claims against Zyprexa, its top-selling anti-psychotic drug. The lawsuits claim that the label on Zyprexa medication boxes failed to provide adequate warning that the drug could put patients at risk for developing diabetes and other glucose abnormalities. The Brown & Crouppen law firm has developed a press release that explains the Zyprexa situation and the importance of filing claims promptly.

(PRWEB) June 15, 2005 -- Brown & Crouppens team of professional lawyers is pursuing claims on behalf of individuals who have taken Zyprexa, an anti-psychotic drug manufactured by Eli Lilly & Co.

Late Thursday, June 9, 2005, Lilly announced that it will settle approximately three-quarters of the liability claims stemming from claims that the label on Zyprexa medication boxes failed to provide adequate warning that the drug could put patients more at risk for developing diabetes.

Zyprexa is the brand name for olanzapine. It is considered an atypical” antipsychotic medication used to treat Schizophrenia and Bipolar Mania. Approved by the Food and Drug Administration (FDA) in 1996, it is thought that Zyprexa works by decreasing the effects of two chemical messengers in the brain, serotonin and dopamine.

Despite evidence dating back to the 1950s that ties the use of drugs similar to Zyprexa to increased risk of diabetes, pancreatitis, hyperglycemia and other pancreas-related illnesses, Eli Lilly & Co. continues to aggressively market the drug – which represented approximately one-third of Lillys $4.3 billion in sales in 2004.

While Eli Lilly continues to enjoy the profits from Zyprexa sales, some feel that patients continue to suffer from the known and newly discovered health risks associated with the drug.

Ron Brown, a partner with Brown and Crouppen stated, "due to the nature of the settlement, time is of the essence to preserve the victim's rights." Anyone who has, or is currently taking the drug Zyprexa and has experienced diabetes or other glucose abnormalities, should contact Brown & Crouppen today.

About Brown & Crouppen:
Brown & Crouppen has been building a reputation for success with personal injury clients for over 25 years. Today, the firm is one of mid-Americas largest personal injury law firms with more than 70 legal professionals and five offices throughout Missouri and Illinois. A major emphasis for Brown & Crouppen is dangerous drug litigation involving manufacturers and suppliers of unsafe drugs and products.

For additional information, please visit http://www.brownandcrouppen.com , http://www.Zyprexa-Lawyers.com

Contact:
Brown & Crouppen, Attorneys at Law
Main Office
720 Olive Street
Suite 1800
St. Louis, MO 63101
1-800-536-HELP
dlawrence@brownandcrouppen.com

###

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Diane Lawrence
Brown & Crouppen, P.C.
1-800-536-4357
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright